Company Overview
Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer. The company was founded in 2018 and is based in Cerritos, California.
Why Investors Should Care
Generates a return on equity of 104.0%, reflecting efficient use of shareholder capital.
Return on capital employed stands at 30.3%.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -17.73% |
| 6 Months: | -69.06% |
| 3 Months: | -48.65% |
| 1 Month: | -29.71% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)34.12 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 104.0%.
- Healthy ROCE of 30.3%.
CONS
- Trading 97.9% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | LIMN Liminatus Pharma, Inc. PHARMA | 3.62 | -0.15 | $4.86M | 0.00% | 30.33% | 103.99% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Operating Income | -247 | -909.22K | -543.15K | -264.22K | -1.12M | -701.17K | -1.10M |
| Net Income | -1.75M | -961.21K | -601.37K | -327.53K | 113.29K | -1.82M | -1.12M |
| Diluted EPS | -2.47 | -0.05 | -0.03 | -0.02 | 0.00 | -0.07 | -0.03 |
| R&D Expense | - | 714.13K | 357.07K | - | - | - | 400.00K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Operating Income | -3.33M | -2.97M |
| Net Income | -3.55M | -10.21M |
| Diluted EPS | -0.20 | -0.43 |
| R&D Expense | 2.69M | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Total Assets | - | 5.41M | 512.79K |
| Total Equity | -15.79M | -19.34M | -9.81M |
| Total Liabilities | - | 24.75M | 10.33M |
| Current Liabilities | - | 24.75M | 10.30M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Operating Cash Flow | -1.45M | -9.96M |
| Investing Cash Flow | -2.85M | -788.11K |
| Financing Cash Flow | 3.92M | 11.03M |
| Capital Expenditure | - | -13.11K |
| Free Cash Flow | - | -9.98M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2024 | Dec 2025 |
|---|---|---|
| Gross Margin % | - | - |
| Operating Margin % | - | - |
| Net Margin % | - | - |
| ROE % | 18.3% | 104.0% |
| ROCE % | 17.2% | 30.3% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Cygnus Capital Advisors, LLC | 0.49% | 6.59K | $22.92K |
| 2 | Xtx Topco Ltd | 0.33% | 4.44K | $15.44K |
| 3 | Geode Capital Management, LLC | 0.21% | 2.77K | $9.63K |
| 4 | Citadel Advisors Llc | 0.08% | 1.12K | $3.90K |
| 5 | Vanguard Capital Management LLC | 0.08% | 1.01K | $3.51K |
| 6 | Goldman Sachs Group Inc | 0.06% | 804 | $2.80K |
| 7 | Stonex Group Inc. | 0.04% | 521 | $1.81K |
| 8 | Vanguard Fiduciary Trust Co | 0.03% | 460 | $1.60K |
| 9 | State Street Corporation | 0.03% | 380 | $1.32K |
| 10 | UBS Group AG | 0.02% | 335 | $1.17K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for LIMN
Korea’s Ministry of Food and Drug Safety authorizes Liminatus study - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxQWmhFaVFmSWQ2eEZLYkhDaGdnN3RGOFREVkU5UHVfTUp6NDlCOU1CcDd2S2s4cHBhaXBNQXNYV0czTWdETEFJNUVVSzFLVzJZbGxMdzFjRGp6N2pybk5nUzFKaDJNUlNfMjl5bUdrdFppTXhSdUtXaF9vcmNXUFVvdVpRa3Rpa095NFY1NW…
Liminatus Pharma (LIMN) Stock Is Trending Overnight — Here’s Why it Spiked Over 30% in After-Hours Session - Sahm
<a href="https://news.google.com/rss/articles/CBMi5wFBVV95cUxQZENwSjR5T1J5bURkTmtHY3FkWm15ZHJ4TDc1VFFkNHlER2NIdlJ2RHFreGRSUUVKSlk4bEE0SmlDbWRjUUJySkQtRW1qbTZWbEhUSmZUaHlweG1hZTlYbHphb3dCdzJMb1NGTGNFbUZWaTdmLUNuNlF3Ui0zd1paM3A3YkxkN1k5cm1udj…
LIMN - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE5HVUNIdFZtQnFIbDduYnQ0ajFnWjhyV2tycVEwQmgtWGl0VzdiTWJiVHo3dk4zdmxBS1pFT1laZlMyMlBtSlE?oc=5" target="_blank">LIMN</a> <font color="#6f6f6f">Finviz</font>…
Liminatus Pharma Is Trending Overnight — Here's Why LIMN Stock Surged Over 79% In After-Hours Session - Benzinga
<a href="https://news.google.com/rss/articles/CBMi6gFBVV95cUxPeWdyd09vdXhDTFdUYXV3SG0wZGtPRmFWR1AzTW1OemRGRlhsT0VoNFNRSEdrWGJLdGNpR09XLVowWG1KdVpHalpiaXNwLWtjOTBJTFctZVBMZktOVkpWbjc2WkJpQVY5d3M4ZVhZVFdOaGtlR1R2UGliNjNaZy03VkwwSkdXalNsZU5rNz…
Price to book forward of Liminatus Pharma, Inc. – NASDAQ:LIMN - tradingview.com
<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxPbC12d1BpMWc2cTJ3Y3NYREVIWm5yUjFCLXplUmJfY2FCalZCUk9tRzFteExURUVjNXJYYXM2aUZILVpzTVNWZnVYMVQ5MFJHUDZobmp4RnlDa0FnZjE4b3MzaUVNOXg0ZFlSaHJXSDZfVS1kcF85VlBuTE9VUjdMVEtFb3UyWVAxblpXQT…
Liminatus Pharma, Inc. Announces Reverse Stock Split of its Common Stock - The Manila Times
<a href="https://news.google.com/rss/articles/CBMi3AFBVV95cUxPYjNYcW5aYWJvVml5cEt4dEp2ZHQ0MVRaZ1lwa2J1clNXTUc0YVVEYWVDblBNem42OWZMOE9hUmxydWtUSmJnaUVudGNJS3ZQMlVqN2k4cUF0MUdzSENhbmRhamxnZ2k4MGpaS1V3MkxGT1hrdExwUEVWQ1ZiMVJnYVNGR2RtZ2E5Si0tUW…
LIMN — Frequently Asked Questions
What is the current share price of Liminatus Pharma, Inc. (LIMN)?
As of 2026-09-19 21:16 PDT, Liminatus Pharma, Inc. (LIMN) trades at $3.62 on NasdaqCM. Its 52-week range is $3.34 to $170.50.
What is the market capitalisation of LIMN?
Liminatus Pharma, Inc. (LIMN) has a market capitalisation of $4.86M on NasdaqCM.
What is the P/E ratio of LIMN?
LIMN trades at a trailing price-to-earnings (P/E) ratio of -0.15. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 12.94.
What is the return on equity (ROE) of LIMN?
LIMN has a return on equity (ROE) of 103.99%. Its return on capital employed (ROCE) is 30.33%.
Is LIMN a good stock to buy?
This page provides a data-driven analysis of Liminatus Pharma, Inc. (LIMN), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.